NEW YORK (GenomeWeb) – Roche said today that its diagnostics division revenues grew 5 percent in the first nine months of 2017, driven by growth in immunodiagnostics and in the rest of its centralized and point-of-care solutions business.

For the nine months ended Sept. 30, the Basel, Switzerland-based pharmaceuticals and diagnostics firm's total revenues rose 5 percent to CHF 39.43 billion ($40.61 billion) from CHF 37.51 billion during the same period in 2016.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.